Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Hizentra for the Treatment of Patients with CIDP

Drug Name

Hizentra® (Immune globulin subcutaneous [human] 20% liquid)

Developer

CSL Behring

Current Indication

Chronic inflammatory demyelinating polyneuropathy (CIDP) disorder

Market Sector

Immunology

Development Status

Approved in the US and Europe
Expand
Close
Close
Close
Globaldata

Identify the key trends in the immuno-oncology market over the next two years

Close

Go Top